SGMT catalyst calendar

Sagimet Biosciences Inc.

Upcoming catalysts
3
Cash runway
83.7 months
Cash & investments
$240M
Phase 3 programs
1

Sagimet Biosciences Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 10, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 83.7 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 8 concluded trials, 75% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 10, 2026 est. Next quarterly earnings (projected) Earnings —
January 15, 2027 Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne Trial Milestone Phase 1
August 15, 2027 Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne Trial Milestone Phase 3

Track SGMT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open SGMT in the tracker

Recent history

DateEventTypePhase
October 1, 2026 8-K filed: Material agreement Corporate —
September 30, 2026 8-K filed: Reg FD disclosure, Other event Filing —
August 13, 2026 8-K filed: Other event Filing —
August 11, 2026 Quarterly results filed (8-K) Earnings —
July 21, 2026 8-K filed: Reg FD disclosure Filing —
June 12, 2026 8-K filed: Leadership change Corporate —
June 3, 2026 8-K filed: Leadership change Corporate —
May 12, 2026 Quarterly results filed (8-K) Earnings —
April 28, 2026 8-K filed: Material agreement Corporate —
April 27, 2026 Quarterly results filed (8-K) Earnings —
April 27, 2026 8-K filed: Reg FD disclosure Filing —
April 21, 2026 8-K filed: Leadership change, Other event Corporate —
March 11, 2026 Quarterly results filed (8-K) Earnings —
February 2, 2026 8-K filed: Reg FD disclosure Filing —
December 18, 2025 8-K filed: Reg FD disclosure, Other event Filing —
December 17, 2025 8-K filed: Other event Filing —
November 13, 2025 Quarterly results filed (8-K) Earnings —
October 23, 2025 8-K filed: Reg FD disclosure Filing —
October 20, 2025 A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants Trial Milestone Phase 1
August 14, 2025 8-K filed: Material agreement Corporate —
August 13, 2025 Quarterly results filed (8-K) Earnings —
June 10, 2025 8-K filed: Leadership change Corporate —
June 4, 2025 8-K filed: Reg FD disclosure Filing —
May 8, 2025 Quarterly results filed (8-K) Earnings —
April 30, 2025 8-K filed: Leadership change Corporate —
December 18, 2023 A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function Trial Milestone Phase 1
October 2, 2023 Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) Trial Milestone Phase 2
December 21, 2022 Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects Trial Milestone Phase 1
October 2, 2021 Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) Trial Milestone Phase 2
June 15, 2017 A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.